Search

everythinglearnresearchcommunity

for

Search:↓

A joke about creating a hair loss treatment in the kitchen, with replies encouraging more jokes.

The user shared a 3-year hair restoration update using 0.5mg dutasteride daily, 5% minoxidil foam twice daily, a 1.5mm derma roller twice a month, and Nizoral shampoo. They reported significant improvement and maintenance of hair, with minimal side effects, and are satisfied with the results at age 40.

The conversation discusses a hair loss treatment called "nanoxidil," which is similar to minoxidil but with better absorption. Users are curious about its effectiveness for hair regrowth.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about finding reputable clinics in Canada or near the US border that offer DUT mesotherapy for hair loss. The user is seeking recommendations and cost information for these treatments.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

People in the Netherlands are discussing reliable sources to buy Minoxidil, with recommendations for local pharmacies and online pharmacies with NL or neighboring country addresses. Concerns include avoiding fake products, insurance coverage, and the legitimacy of certain online sellers like Foligain and Biovea.

The user added microneedling to their routine of minoxidil and finasteride, resulting in noticeable hair regrowth after three months. They shared photos showing significant improvement.

The conversation is about finding affordable RU58841 for hair loss treatment. Suggestions include buying it in powder form and making a solution at home, with Amazon as a potential source.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

Norwood 1-3 hair loss is considered normal in Russia and not balding. Using finasteride for Norwood 1-3 is seen as unnecessary and risky.

The user is unhappy with their hair transplant results, feeling the hairline looks unnatural, but most commenters reassure them it looks good and natural. Some suggest styling changes or focusing on hair care routines.

The user shared progress in hair regrowth using finasteride, minoxidil, a dermaroller, hair/nails gummies, and rosemary oil. They expressed gratitude for the support from the group and relief about their appearance for an upcoming wedding.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

A user underwent a 2,550 FUE hair transplant and started taking dutasteride 0.5mg. They previously tried RU58841, minoxidil, and microneedling but avoided finasteride and dutasteride due to side effects.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

A user traveled to Turkey to buy 72 packages of Dutasteride for a year-long supply and successfully brought them back home. They plan to use 2.5mg of Dutasteride daily along with RU58841 for hair loss.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

A 21-year-old is using finasteride and previously used minoxidil for hairline concerns, considering a hair transplant despite no visible balding. They are advised to continue finasteride as a preventive measure.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation discusses that genetic analysis of the Iceman Ötzi shows he had male-pattern baldness and dark skin, with a joke about using beards and tattoos to distract from hair loss. No specific hair loss treatments are mentioned.

A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.